Bupropion for weight reduction

Authors: Gadde, Kishore M; Xiong, Glen L

Source: Expert Review of Neurotherapeutics, Volume 7, Number 1, January 2007 , pp. 17-24(8)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Bupropion is a norepinephrine and dopamine uptake inhibitor that has been available for several years for the treatment of depression and aiding smokers to quit. Although bupropion is not approved for treating obesity, three randomized clinical trials have shown some degree of efficacy for this drug in promoting weight loss in obese patients. The present drug profile provides a review of the pharmacology of bupropion, clinical evidence of efficacy with regard to weight reduction, tolerability and risks, and the current and future role of this drug in the management of obesity.

Keywords: antiobesity drugs; bupropion; obesity; weight loss

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14737175.7.1.17

Publication date: 2007-01-01

More about this publication?

Expert Review of Neurotherapeutics provides expert commentary on the use of drugs and medicines in clinical neurology and neuropsychiatry. Coverage includes disease management, new medicines and drugs in neurology, therapeutic indications, diagnostics, medical treatment guidelines and neurological diseases such as stroke, epilepsy, Alzheimer's and Parkinson's.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites